Alisertib and pembrolizumab in Rb-deficient head and neck squamous cell carcinomas (HNSCC)

Category Primary study
JournalMolecular Cancer Therapeutics
Year 2023
This article has no abstract
Epistemonikos ID: 74ba7d9b4c27d60120afc10c0f649006e1686d13
First added on: Feb 17, 2025